Welcome to 2024 from the International Myeloma Foundation


The IMF Thanks You for Your Year-End Contributions! Because of the support of generous myeloma community members like YOU, the International Myeloma Foundation (IMF) is able to continue with its mission. We look forward to beginning 2024 on all cylinders—continuing our drive for myeloma Research, Education, Support, and Advocacy. Together, we are improving lives and working toward prevention and a cure. If you would like to give in other ways to our mission, we encourage you to check out the Myeloma ACTION Team


Keep Your Eye Out for the Replay: Top Myeloma Research at ASH 2023 from a Patient Perspective Earlier today, IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie discussed important Top Myeloma Research and Key Takeaways from the 2023 American Society of Hematology (ASH) Conference, along with a panel of patient advocates including Jessie Daw, PhD, and Michael Tuohy. Together, they sifted through the data of 1,000+ myeloma-related abstracts from the ASH conference and presented key points in approachable terms for everyday decision-making. The replay of this webinar will be available in the coming days. Keep your eye on the link below.


Register Early for the March for Myeloma 5K Run/Walk This isn't just a run; it's a force for change. During March, we're creating a global wave of awareness for myeloma. This Myeloma ACTION Month, march alongside others in the myeloma community and help us make waves of awareness that touch every corner of the globe. Join us in-person in Boca Raton, FL, or race virtually from wherever you are on Friday, March 15, 2024, at 7:00 a.m EST as we make this journey a pivotal part of Myeloma Action Month 2024.


Watch the Replay: IMWG Conference Series 2023: Making Sense of Treatment Presented on Thursday, December 14, 2023, the IMWG Conference Series, “Making Sense of Treatment" featured leading myeloma experts who discussed the latest myeloma research news from the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition. IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie moderated the discussion, with Drs. María V. Mateos (University of Salamanca—Salamanca, Spain) and Thomas Martin (University of California San Francisco—San Francisco, CA) serving as panelists. The replay and slides are available at the button below.


Around the Web: Myeloma News To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. Learn about the DREAMM-6 Trial and how it studies lower dosing of belantamab mafodotin. This article in STAT discusses that the “Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.” In this article in Oncology Nursing News, a nurse discusses the care relapsed/refractory multiple myeloma patients need when undergoing CAR T-cell Therapy. As always, we invite you to visit the IMF Newsroom for the most recent myeloma news.

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

KTX-1001 (phase I trial – Now Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Fully Accrued)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Webinar Replays

Watch the Replay
IMF Patient and Family Webinar

Watch the Replay
M-Power Tampa

Watch the Replay
IMF Virtual Regional Community Workshop

See also, all of our events.

We Thank Our Sponsors:

AbbVie, Bristol Myers Squibb, GSK, Janssen Oncology, Karyopharm Therapeutics,
Pfizer, and Takeda Pharmaceuticals U.S.A., Inc.

We also thank individuals like you for your continued support!

Join the conversation at The International Myeloma Foundation

Facebook: /Myeloma | Twitter @IMFMyeloma | Instagram @IMFmyeloma

www.myeloma.org

This email was sent to by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873

We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Manage Subscriptions • Privacy Policy

View as web page